Vibegron

Vibegron (MK-4618) is a potent, highly selective and orally active β3-adrenoceptor agonist (EC50=1.1 nM) . Vibegron can be used for severe urgency urinary incontinence related to overactive bladder[1][2][3].

Product Specifications

CAS Number

[1190389-15-1]

Product Name Alternative

MK-4618

UNSPSC

12352005

Hazard Statement

H315, H319, H320

Target

Adrenergic Receptor

Type

Reference compound

Related Pathways

GPCR/G Protein; Neuronal Signaling

Applications

Neuroscience-Neuromodulation

Field of Research

Others

Assay Protocol

https://www.medchemexpress.com/vibegron.html

Concentration

10mM

Purity

98.03

Solubility

DMSO : 95 mg/mL (ultrasonic)

Smiles

O=C([C@@H]1CCC2=NC=CC(N21)=O)NC3=CC=C(C[C@H]4N[C@@H]([C@H](O)C5=CC=CC=C5)CC4)C=C3

Molecular Formula

C26H28N4O3

Molecular Weight

444.53

Precautions

H315, H319, H320

References & Citations

[1]Yoshida M, et al. Efficacy of vibegron, a novel β3-adrenoreceptor agonist, on severe urgency urinary incontinence related to overactive bladder: post hoc analysis of a randomized, placebo-controlled, double-blind, comparative phase 3 study. BJU Int. 2020;125 (5) :709-717.|[2]Yoshida M, et al. Efficacy of novel β3 -adrenoreceptor agonist vibegron on nocturia in patients with overactive bladder: A post-hoc analysis of a randomized, double-blind, placebo-controlled phase 3 study. Int J Urol. 2019;26 (3) :369-375.|[3]Edmondson SD, et al. Discovery of Vibegron: A Potent and Selective β3 Adrenergic Receptor Agonist for the Treatment of Overactive Bladder. J Med Chem. 2016;59 (2) :609-623.|[4]Gotoh D, et al. Effects of a new β3-adrenoceptor agonist, vibegron, on neurogenic bladder dysfunction and remodeling in mice with spinal cord injury. Neurourol Urodyn. 2020;39 (8) :2120-2127.|[5]Furuta A, et al. Additive effects of intravenous and intravesical application of vibegron, a β3-adrenoceptor agonist, on bladder function in rats with bladder overactivity. Naunyn Schmiedebergs Arch Pharmacol. 2020;393 (11) :2073-2080.